Business
INVO Bioscience Announces Four Individual Poster Abstracts Discussing the Benefits of INVOcell Presented at the 2021 American Society for Reproductive Medicine (ASRM) Congress & Expo
SARASOTA, Fla. and BALTIMORE, Oct. 20, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the
About this update from Invo Fertility, Inc.
[{"type":"text","content":"SARASOTA, Fla. and BALTIMORE, Oct. 20, 2021 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world's only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, today announced that four poster abstracts were presented discussing INVOcell at the 77th Scientific Congress & Expo of the American Society for Reproductive Medicine (ASRM) being held this week in Baltimore, Maryland.\n\n \n \n \n \n \n \n\n \nSteve Shum, CEO of INVO Bioscience, commented, \"It's extremely rewarding to see our technology highlighted at this year's ASRM. Four independent abstracts were selected for presentation at the fertility industry's most prominent annual meeting.\"\n\"On behalf of the entire INVO team, we sincerely appreciate the work of the many clinicians that now support INVOcell as a solution and thank those that contributed their independent work in advancing the understanding of the unique capabilities of INVOcell. These types of events and studies emphasize the opportunity we have to democratize advanced fertility services through the unique attributes of the INVOcell solution and bring care to the large, underserved patient population around the world,\" Mr. Shum concluded.\nA summary of each poster abstract is provided below with additional details of each available on the INVO Bioscience website at https://invobioscience.com/resources/.\nIS IN VIVO BETTER THAN IN VITRO? A COMPARISON OF SIBLING EMBRYO DEVELOPMENT AND PREGNANCY RATES THROUGH INVOCELL AND CONVENTIONAL IVF. \nTaeshin Kim, Ph.D.,1 Callie Barnwell Gibson, Ph.D.,1 Lauren N. C. Johnson, MD, MSCE,1 Meaghan Bowling, MD,1 John K. Park, MD,1 Bill Meyer, MD,1 Sung Tae Kim, PhD, HCLD2 \n1Carolina Conceptions, Raleigh, NC; 2University Hospitals Fertility Center/Case Western Reserve University, Beachwood, OH\nCONCLUSIONS: Our result suggests that blastocyst formation from INVOCELL intravaginal culture performs slightly better than that of in vitro culture although overall number of usable blastocysts, blastocyst development rate per inseminated oocytes, and pregnancy outcomes are not significantly different.\nUSE OF INVOCELL INTRAVAGINAL EMBRYO CULTURE SYSTEM FOR FIVE DAYS OF INCUBATION: A PROSPECTIVE STUDY OF SAFETY AND TOLERABILITY. \nKaren R. Hammo...